The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.

Inclusion Criteria:

• Age greater than or equal to (>=)18 years.
• Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea.
• Participant voluntarily consent to participate in the study.

Exclusion criteria:

• Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label.
• Participants actively participating in other interventional clinical trial(s) on mCRC treatments.
• Pregnant or breastfeeding women.

Participants with mCRC in South Korea who initiate the first treatment with Fruzaqla according to the approved indication will be included in this study.

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.